News & Press Releases

Endpoints News quoted Immigration Practice Chair John Quill in an article on the Trump administration’s proposal to require a $100,000 payment for new H-1B visa petitions. The article highlights potential implications for the biotech sector, noting that the change could make it more difficult for companies to recruit international workers with specialized technical skills, which may affect scientific innovation.

Quotes from Partner Anthony de Fazekas were shared by Communitech in an article about how Canada can use intellectual property to protect its innovations and benefit from the value they generate. The article notes that Canada could benefit from strengthening its IP strategy to help ensure that the value of its technology stays within Canada.

Peter Saparoff, Chair of Mintz’s Institutional Investor Class Action Recovery Practice, and Associate Sofia Nuño published an article in Bloomberg Law examining how state attorneys general are increasingly applying antitrust and consumer-protection laws to asset managers’ ESG and AI stewardship practices, marking a shift toward more aggressive state-level enforcement beyond federal oversight.

Health Law Practice Chair and Health Care Enforcement Defense Co-chair Karen Lovitch was quoted in a recent The Dark Report article on a recent court ruling interpreting the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) and its implications for clinical labs that use independent contractors for marketing. The court decided that while paying independent sales and marketing representatives on a percentage basis is not by itself an EKRA violation, compensation arrangements could still cross the line if marketers exert “undue influence” on physicians.

Law360 featured commentary from Jason P.W. Halperin in an article about a pharmaceutical industry insider trading case brought by the DOJ. Jason and Elizabeth Platonova represented one of the defendants and negotiated a resolution in which he pled guilty and was sentenced to 15 months in prison.

The Deal quoted Member Theresa Carnegie in a recent article about how regulatory pressure on pharmacy benefit managers (PBMs) has sparked innovation and opened up investment opportunities in the industry. Increased scrutiny of larger PBMs over concerns about competition and drug prices has prompted newer PBMs to emphasize transparency.